Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 26:6:247.
doi: 10.3389/fphar.2015.00247. eCollection 2015.

HDL as a drug and nucleic acid delivery vehicle

Andras G Lacko  1 , Nirupama A Sabnis  1 , Bhavani Nagarajan  2 , Walter J McConathy  3
Affiliations
Review

HDL as a drug and nucleic acid delivery vehicle

Andras G Lacko et al. Front Pharmacol. .

Abstract

This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.

Keywords: HDL; drug delivery; lipoproteins; nucleic acid delivery; therapeutics.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Localization of a hydrophobic drug (paclitaxel) in the core region of synthetic (reconstituted) HDL (rHDL). Adapted from Weinberg (1987).
See this image and copyright information in PMC

References

    1. Bali K. K., Kuner R. (2014). Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol. Med. 20, 437–448. 10.1016/j.molmed.2014.05.006 - DOI - PMC - PubMed
    1. Bijsterbosch M. K., Rump E. T., De Vrueh R. L. A., Dorland R., van Veghel R., Tivel K. L., et al. (2000). Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 28, 2717–2725. 10.1093/nar/28.14.2717 - DOI - PMC - PubMed
    1. Bozzuto G., Molinari A. (2015). Liposomes as nanomedical devices. Int. J. Nanomed. 10, 975–999. 10.2147/IJN.S68861 - DOI - PMC - PubMed
    1. Connelly M. A., Williams D. L. (2004). SR-BI and HDL cholesteryl ester metabolism. Endocr. Res. 30, 697–703. 10.1081/ERC-200043979 - DOI - PubMed
    1. Counsell R. E., Pohland R. C. (1982). Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem. 25, 1115–1120. 10.1021/jm00352a001 - DOI - PubMed